Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248141 · ClinicalTrials.gov registry record
Understanding Hemophilia A and B Drug Dosage Administration Patterns
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 11
- Enrollment target
NCT03248141: Clinical Trial study, sponsored by Pfizer.
NCT03248141 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03248141 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate. Physicians complete a retrospective chart review on each enrolled patient. Patients will complete a one-time study questionnaire.
Interventions
- DRUG Hemophilia B standard half-life
- DRUG Hemophilia B extended half-life
- DRUG Hemophilia A standard half-life
- DRUG Hemophilia A extended half-life
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-03-14 |
Why NCT03248141 stopped before completion
NCT03248141 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Hemophilia B standard half-life is the first listed.
NCT03248141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03248141 about?
NCT03248141 is a clinical study titled "Understanding Hemophilia A and B Drug Dosage Administration Patterns". Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate...
What is the current status of trial NCT03248141?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2017-09-01. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT03248141?
The interventions under investigation include: Hemophilia B standard half-life (DRUG), Hemophilia B extended half-life (DRUG), Hemophilia A standard half-life (DRUG), Hemophilia A extended half-life (DRUG).
Who is sponsoring clinical trial NCT03248141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI